Hainan Poly Pharm Co Ltd (300630) - Total Assets
Based on the latest financial reports, Hainan Poly Pharm Co Ltd (300630) holds total assets worth CN¥6.25 Billion CNY (≈ $915.21 Million USD) as of September 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See what is Hainan Poly Pharm Co Ltd's book value for net asset value and shareholders' equity analysis.
Hainan Poly Pharm Co Ltd - Total Assets Trend (2016–2023)
This chart illustrates how Hainan Poly Pharm Co Ltd's total assets have evolved over time, based on quarterly financial data.
Hainan Poly Pharm Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2023)
Hainan Poly Pharm Co Ltd's total assets of CN¥6.25 Billion consist of 36.2% current assets and 63.8% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 6.4% |
| Accounts Receivable | CN¥1.20 Billion | 19.0% |
| Inventory | CN¥359.05 Million | 5.7% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥817.09 Million | 13.0% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2016–2023)
This chart illustrates how Hainan Poly Pharm Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 300630 company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hainan Poly Pharm Co Ltd's current assets represent 36.2% of total assets in 2023, a decrease from 39.7% in 2016.
- Cash Position: Cash and equivalents constituted 6.4% of total assets in 2023, down from 23.1% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 13.0% of total assets, an increase from 6.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 19.0% of total assets.
Hainan Poly Pharm Co Ltd Competitors by Total Assets
Key competitors of Hainan Poly Pharm Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
|
USA | $5.76 Million |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥31.46 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867
|
China | CN¥8.15 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Guobang Pharma Ltd
SHG:605507
|
China | CN¥10.58 Billion |
Hainan Poly Pharm Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.56 | 1.93 | 1.57 |
| Quick Ratio | 1.18 | 1.64 | 1.41 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥784.27 Million | CN¥1.31 Billion | CN¥245.14 Million |
Hainan Poly Pharm Co Ltd - Advanced Valuation Insights
This section examines the relationship between Hainan Poly Pharm Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.18 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 5.5% |
| Total Assets | CN¥6.29 Billion |
| Market Capitalization | $73.10 Million USD |
Valuation Analysis
Below Book Valuation: The market values Hainan Poly Pharm Co Ltd's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Hainan Poly Pharm Co Ltd's assets grew by 5.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Hainan Poly Pharm Co Ltd (2016–2023)
The table below shows the annual total assets of Hainan Poly Pharm Co Ltd from 2016 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | CN¥6.29 Billion ≈ $919.94 Million |
+5.50% |
| 2022-12-31 | CN¥5.96 Billion ≈ $871.99 Million |
+27.81% |
| 2021-12-31 | CN¥4.66 Billion ≈ $682.23 Million |
+52.56% |
| 2020-12-31 | CN¥3.06 Billion ≈ $447.19 Million |
+77.64% |
| 2019-12-31 | CN¥1.72 Billion ≈ $251.73 Million |
+55.13% |
| 2018-12-31 | CN¥1.11 Billion ≈ $162.28 Million |
+26.81% |
| 2017-12-31 | CN¥874.53 Million ≈ $127.97 Million |
+98.88% |
| 2016-12-31 | CN¥439.72 Million ≈ $64.35 Million |
-- |
About Hainan Poly Pharm Co Ltd
Hainan Poly Pharm. Co., Ltd. engages in research, development, production, and sale of pharmaceutical drugs in China and internationally. The company's dosage formulations comprise of tablets, capsules, granules, ointments, eye drops, pre-infusion, injection, lyophilization, and oral solutions. It also offers pharmaceutical preparations, active pharmaceutical ingredients, other raw materials, exc… Read more